The UK’s NHS and Novartis have, as of Monday 13 Jan 2020, announced a pact which will clear the way for an accelerated review by the country’s health watchdog, NICE, of heart drug inclisiran, which could make it broadly available as soon as 2021.
Boost in Sales
Novartis hopes that the NHS deal will boost the sales of cholesterol-lowering inclisiran, which the Swiss drug maker bought in a deal which was announced last year for nearly $10m, and also predicts that it will be a top seller.
Please register or login to comment!
Register now Login